# OnCo record paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019" ;
  schema:name "Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data"@en ;
  schema:description "Small-cell lung cancer, treated as one disease for fifty years, is at least four. The subtypes are named after the transcription factor each one leans on: ASCL1, NeuroD1, YAP1 and POU2F3."@en ;
  schema:url <https://onco.cc/key-papers/paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1038/s41568-019-0133-9>, <https://pubmed.ncbi.nlm.nih.gov/30926931/>, <https://europepmc.org/article/MED/31175338>, <https://doi.org/10.1038/s41568-019-0133-9> ;
  onco:tag "lung-evidence" ;
  schema:sameAs <https://doi.org/10.1038/s41568-019-0133-9> ;
  schema:datePublished "2019"^^xsd:gYear ;
  schema:author "Rudin CM, Poirier JT, Byers LA, et al." ;
  onco:related <https://onco.cc/key-papers/paper-george-sclc-genomic-profiles-nature-2015/>, <https://onco.cc/key-papers/paper-ahn-dellphi-301-tarlatamab-sclc-nejm-2023/>, <https://onco.cc/ideas/idea-sclc-subtype-directed/> ;
  onco:cancers <https://onco.cc/cancers/lung-cancer/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/limited-stage-sclc/>, <https://onco.cc/cancers/extensive-stage-sclc/> ;
  onco:sections <https://onco.cc/fronts/drug-discovery/>, <https://onco.cc/fronts/diagnostics/> ;
  onco:technologies <https://onco.cc/technologies/rna-seq/>, <https://onco.cc/technologies/organoids/> ;
  onco:targets <https://onco.cc/targets/dll3/>, <https://onco.cc/targets/ascl1/>, <https://onco.cc/targets/yap1/>, <https://onco.cc/targets/myc-gene/>, <https://onco.cc/targets/mycl/> ;
  onco:institutions <https://onco.cc/institutions/mskcc/>, <https://onco.cc/institutions/md-anderson/> ;
  onco:pathways <https://onco.cc/pathways/sclc-signalling/>, <https://onco.cc/pathways/lineage-plasticity-neuroendocrine/>, <https://onco.cc/pathways/transcription-addiction/>, <https://onco.cc/pathways/myc/> ;
  onco:terms <https://onco.cc/terms/histology/>, <https://onco.cc/terms/driver-mutation/> ;
  onco:people <https://onco.cc/people/charles-rudin/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-rare-cancers/>, <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-trial-design/> ;
  onco:journals <https://onco.cc/journals/nature-reviews-cancer/> .